Press Release: October 15, 2024

Novelna Welcomes Mark Morgan to Advisory Board, Expanding Expertise in U.S. Market Access and Healthcare Innovation

Palo Alto, California – Novelna, a biotech company specialized in proteomics-based cancer detection, is pleased to announce the appointment of Mark Morgan to its advisory board. With over 30 years of experience in healthcare and biotechnology, Morgan brings deep expertise in U.S. market access, healthcare system partnerships, and operational leadership.

Mark Morgan, MBA – Market Access

Throughout his distinguished career, Morgan has held senior roles at leading healthcare organizations. He previously served as President of Anthem Blue Cross in California, where he led the company’s strategy and operations during a time of significant healthcare reforms. He also held the position of Senior Vice President of Network Management and Provider Partnerships at Blue Shield of California, where he improved provider networks and strengthened healthcare collaborations.  At Amgen, as Executive Director of Value & Access, Morgan was instrumental in developing value-based care models that enhanced patient outcomes. Most recently, he was the President of UCB’s US Operations.

Morgan was also the Senior Vice President of Market Access and Health Systems Partnerships at GRAIL, where he focused on integrating cutting-edge cancer detection technologies into healthcare systems, driving access to innovative diagnostics. His experience across diverse healthcare settings will be invaluable as Novelna continues to advance its early cancer detection technologies.

“We are committed to addressing the needs of patients, providers, and payers as we develop and launch our products,” said Ashkan Afshin, CEO of Novelna. “Mark’s expertise will help us navigate the needs of payers and health systems, ensuring that our innovations are accessible and impactful across the healthcare landscape.”

For more information about Novelna and its advisory board, please visit www.novelna.com.

Contact Information: info@novelna.com

About Novelna Inc.: Novelna is a proteomics-based liquid biopsy startup, transforming cancer diagnostics. Our mission is simple: ensure early disease detection is not a privilege, but a right for all. By advancing diagnostic technologies, we are committed to securing a healthier and brighter future globally.